STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, today announces that it presented promising data from its ...

Theramex has announced that the Scottish Medicine Consortium (SMC) has recommended Yselty® for the treatment of moderate to severe symptoms of uterine fibroids (UFs) aligned to the product indication ...

At Pack Expo US 2024, ACG Inspection will be debuting its groundbreaking Life Sciences Cloud - a complete end-to-end analytical and traceability solution which aims to deliver production quality, ...

In accordance with the resolution of the Annual General Meeting on May 14th, 2024, the Chairman of the Board has contacted the company’s two largest shareholders or group of shareholders in terms of ...

TG4050: Promising Phase I data to be presented at SITC 2024 providing clinical proof of principle in adjuvant head and neck cancer setting Financial visibility confirmed into Q4 2025 Strasbourg, ...

GENEVA, SWITZERLAND / ACCESSWIRE / November 11, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering ...

Institutional Investment of £600,000Hemogenyx Pharmaceuticals Secures £0.6m for Phase I Clinical Trials LONDON, UNITED KINGDOM / ACCESSWIRE / November 11, 2024 / Hemogenyx Pharmaceuticals plc ...

ENRICHED CTCS AND CTDNA PROVIDES COMPLEMENTARY INFORMATION IN NSCLC PATIENTS TREATED WITH ASTRAZENECA'S OSIMERTINIBThe addition of CTC-DNA analysis to clinical trials could identify patients ...

The global hepatitis B diagnostic tests market is on the cusp of substantial expansion, driven by a combination of increasing disease incidence, heightened global awareness campaigns, and rapid ...

The global continuous peripheral nerve block catheter market is poised for significant growth, with revenues expected to rise from USD 585.6 million in 2023 to USD 1,058.6 million by 2033, ...